Enovis announced that CEO Matt Trerotola has notified its board of directors of his intent to retire from his role as CEO of the company. This would become effective upon his successor’s appointment by the board and assuming the CEO position.

The board is currently working with an executive search firm to pick a new leader to serve as the company’s CEO. Once the successor is named, Enovis and Trerotola will enter a retirement and transition agreement. He has agreed to continue as an employee and executive advisor to the company and his successor for a year from the appointment date.

“Working with the exceptionally talented team at Enovis has been a great honor,” said Trerotola. “I am deeply proud of all that we have accomplished over my tenure. Today, Enovis is a global company that is well positioned for continued growth thanks to our high-quality portfolio, focus on continuous improvement and exceptional team. Given the Company’s strong position, now is the right time to plan the transition to our next leader. I am excited to work closely with the Board to support a smooth handover and look forward to watching the business continue its industry leadership and above-market growth.”

Trerotola has served as Enovis’ CEO since April 2022. Before that, he led Colfax Corporation from 2015 to 2022.

“The Board is incredibly thankful for Matt’s years of stewardship at Enovis and Colfax,” added Sharon Wienbar, Lead Independent Director at Enovis. “Matt has been instrumental in driving Enovis’ transformation into a leading global MedTech innovator. Matt has played a pivotal role in shaping the Company’s evolution, driving innovation and fostering a strong culture of excellence. The Board remains committed to our strategy of growth through innovative, industry-leading solutions that improve patient outcomes. We also look forward to appointing a CEO who will continue to drive efficiency with our EGX business system and culture.”

Q4 and full-year results

Enovis posted $561 million of revenue in Q4 2024, growing 23% on a reported basis and 6% on a comparable sales basis from Q4 2023. These results reflect growth in Global Reconstructive (Recon)—including the acquisition of Lima—and stable executive in Prevention & Recovery (P&R).

The company’s full-year revenue of $2.1 billion ascended 23% on a reported basis and 6% on a comparable sales basis. Net sales in Recon grew 60% on a reported basis with 9% comparable sales growth, and P&R grew 2% on a reported basis and 3% on a comparable sales basis.

“Our performance in 2024 marks a transformational year for the Company as we executed our integration plans and solidified our ability to deliver sustainable high-single-digit organic growth and year-over-year margin expansion,” said Trerotola. “Our strong finish in 2024 has set a solid foundation for 2025 with key new product launches positioned to drive above market growth rates.”

The company announced financial expectations for 2025 would be in the range of $2.19-2.22 billion, reflecting 6-6.5% organic revenue growth.